There are a number of problems that limit the clinical use of these antibodies. One of these is the generation of an immune response by the patient to the administered murine monoclonal. Another is the effective labelling of the antibody without a loss in binding activity. We have attempted to overcome these problems by engineering surface cysteine residues for site-specific attachment into a mouse: human chimaeric antibody
No takes yet. Share an insight, caveat, or question.
Mountain et al. (1992) studied this question.